
Zerigo delivers safe, effective, in-home phototherapy for psoriasis, eczema and vitiligo, backed by clinical oversight, proven adherence and dedicated support.
Phototherapy is a clinically proven, guideline supported treatment for certain chronic skin conditions. Yet it remains underutilized due to logistical and administrative challenges, limited tools to monitor adherence and patient support in in-home settings.
Patients often wait months for in-office treatments, leading to worsening symptoms and low patient satisfaction
Complex prior authorization processes, billing hurdles and documentation requirements burden staff
Lack of real-time visibility into patient adherence makes at-home treatment difficult to manage
Zerigo removes the traditional barriers to in-home phototherapy, making it easier to prescribe, manage and scale home-based treatment. It’s clinically supported, patient-friendly and seamlessly integrates into your existing workflows.
Narrowband ultraviolet light (NB-UVB) device used for at-home or on-the-go treatment, backed by clinical research.
Remotely monitors and engages patients, and easily accesses treatment data - in real time - to help provide interventions where and how patients need them.
Licensed professionals support treatment and refer patients back to providers as-needed to extend your care beyond the clinic.
A dedicated team takes on administrative burdens of documentation, reporting, eligibility and prescription processing.
*Zerigo Health’s ultraviolet-light-emitting medical device is intended for use in localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). The device can be used at home or in a physician’s office. Individual results may vary. U.S. federal law restricts this device to sale by or on the order of a physician.
**These comparisons are based on extrapolations and/or published results from multiple studies, provided for informational purposes only, and have not been confirmed in head-to-head studies. Treatment outcomes/experiences vary.
Your Clinical Partner for At-Home UVB Therapy
Zerigo doesn’t just deliver a device. We’ve built a turnkey, scalable model of care, backed by a dedicated team to support providers and patients alike.
Description: 80% of members achieved clear/almost clear skin at 12 weeks6, with a 4.9/5 patient satisfaction7 rating and 75% adherence8.
No prior authorization needed. Zerigo works with your current enterprise systems.
Evidence-based training and resources available on-demand, and 1:1 support for on-boarding, training and questions.
1.https://pmc.ncbi.nlm.nih.gov/articles/PMC8953825/
2. Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic - PMC
3. Wu JJ, Feldman SR, Guillemin I, et al. Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial. JAMA Dermatol. 2024;160(12):1320–1328. doi:10.1001/jamadermatol.2024.2877
4. Study Details | Light Treatment Effectiveness (LITE) Study | ClinicalTrials.gov
5. Full article: Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies
6. Member self-reported skin clearance, psoriasis, 2018–2024
7. Member self-reported satisfaction with Zerigo Skin Health Platform
8. Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis – PMC